These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34235418)

  • 1. Severe drug-induced liver injury caused by levetiracetam - A case report and review of the literature.
    Rogalewski A; Zuhorn F; Wilkens L; Krüger M; Klingebiel R; Schäbitz WR
    Epilepsy Behav Rep; 2021; 16():100464. PubMed ID: 34235418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Rare Case of Drug-Induced Liver Injury Caused by Levetiracetam.
    Kawaguchi T; Tominaga T
    Asian J Neurosurg; 2019; 14(3):878-882. PubMed ID: 31497118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the clinical characteristics of the liver injury induced by levetiracetam.
    Sun W; He Y; Li Z; Wang C
    J Pharm Pharmacol; 2022 Mar; 74(3):409-414. PubMed ID: 35089342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levetiracetam in toxic seizures.
    Lee T; Warrick BJ; Sarangarm P; Alunday RL; Bussmann S; Smolinske SC; Seifert SA
    Clin Toxicol (Phila); 2018 Mar; 56(3):175-181. PubMed ID: 28753046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suspected Levetiracetam-Induced Rhabdomyolysis: A Case Report and Literature Review.
    Moinuddin IA
    Am J Case Rep; 2020 Oct; 21():e926064. PubMed ID: 33112844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use.
    Teschke R; Danan G
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiosyncratic drug-induced liver injury: an overview.
    Hussaini SH; Farrington EA
    Expert Opin Drug Saf; 2007 Nov; 6(6):673-84. PubMed ID: 17967156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study.
    Del Bianco C; Placidi F; Liguori C; Mari L; Ulivi M; Ornello R; Pisani A; Mercuri NB; Izzi F
    Epilepsy Behav; 2019 May; 94():178-182. PubMed ID: 30959275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center.
    Green SF; Hare N; Kassam M; Rugg-Gunn F; Koepp MJ; Sander JW; Rajakulendran S
    Epilepsy Behav; 2022 Oct; 135():108868. PubMed ID: 35985166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute liver injury induced by levetiracetam and temozolomide co-treatment.
    Khoury T; Chen S; Abu Rmeileh A; Daher S; Yaari S; Benson AA; Cohen J; Mizrahi M
    Dig Liver Dis; 2017 Mar; 49(3):297-300. PubMed ID: 28034663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Drug Monitoring of Levetiracetam in Select Populations.
    Jarvie D; Mahmoud SH
    J Pharm Pharm Sci; 2018; 21(1s):149s-176s. PubMed ID: 30096051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Rare Case of Levetiracetam and Drug-Induced Idiopathic Aseptic Meningitis in a Pediatric Patient.
    McDonald D; Sultan R; Viswanathan A; Siu A
    Pharmacotherapy; 2019 Jan; 39(1):109-113. PubMed ID: 30488976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An interaction study of Ocimum sanctum L. and levetiracetam in pentylenetetrazole kindling model of epilepsy.
    Sarangi SC; Pattnaik SS; Katyal J; Kaleekal T; Dinda AK
    J Ethnopharmacol; 2020 Mar; 249():112389. PubMed ID: 31739106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of Levetiracetam and Valproic Acid Due to Adverse Effects in Early Post-traumatic Seizure Prophylaxis.
    Pathak SM; Ziechmann R; Menzer J; Hoeft A; Villanueva P
    Cureus; 2023 Oct; 15(10):e47742. PubMed ID: 38021754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals.
    Lammert C; Einarsson S; Saha C; Niklasson A; Bjornsson E; Chalasani N
    Hepatology; 2008 Jun; 47(6):2003-9. PubMed ID: 18454504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring and the therapeutic reference range of levetiracetam for Chinese patients: Problems and issues.
    Shi M; Liu C; He L; Wu H; Wu Y
    Seizure; 2023 Jul; 109():26-33. PubMed ID: 37192596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Tolerability of Rapid Administration Undiluted Levetiracetam.
    Morgan O; Medenwald B
    Neurocrit Care; 2020 Feb; 32(1):131-134. PubMed ID: 30919301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
    Szaflarski JP; Sangha KS; Lindsell CJ; Shutter LA
    Neurocrit Care; 2010 Apr; 12(2):165-72. PubMed ID: 19898966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy.
    Gulcebi MI; Kendirli T; Turgan ZA; Patsalos PN; Onat Yilmaz F
    Epilepsy Res; 2018 Dec; 148():17-22. PubMed ID: 30326332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.